{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:01:34Z","timestamp":1786118494116,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Current tyrosine kinase inhibitors (TKIs) targeting oncogenic KIT and PDGFRA have improved patient outcomes, yet off-target toxicities and drug resistance mutations remain major clinical challenges. Many approved TKIs, often repurposed from other cancer indications, harbor diverse hinge-binding motifs that limit activity against resistance mutations clustering in the ATP-binding pocket of the kinase domain. Here, we describe a structure-based scaffold-hopping strategy to design kinase inhibitors with selectivity for mutant KIT\/PDGFRA. Using structure-activity relationship (SAR) studies and 14 determined co-crystal structures, including a structure of the PDGFRA-G680R solvent-front mutation, we define key molecular interactions underlying resistance and inhibitor selectivity. Our lead 6,7-quinazoline-based inhibitors show high potency against clinically relevant KIT\/PDGFRA mutations and effectively suppress downstream signaling. These compounds provide selective chemical tools to interrogate resistance mechanisms, and the PDGFRA-G680R structure shows the molecular basis for targeting solvent-front mutations across oncogenic kinases.<\/jats:p>","DOI":"10.1038\/s41467-026-76340-7","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:54:26Z","timestamp":1786031666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-7791","authenticated-orcid":false,"given":"T.","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1655-0715","authenticated-orcid":false,"given":"M.","family":"Beerbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-611X","authenticated-orcid":false,"given":"A.","family":"Scrima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1934-1860","authenticated-orcid":false,"given":"H.","family":"Jantzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-8735","authenticated-orcid":false,"given":"A.","family":"Teuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-8857","authenticated-orcid":false,"given":"T.","family":"M\u00fchlenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Garcia-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-1626","authenticated-orcid":false,"given":"A.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Berner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6103-7371","authenticated-orcid":false,"given":"J.","family":"Weisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-8933","authenticated-orcid":false,"given":"M. P.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-6565","authenticated-orcid":false,"given":"S.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-4507","authenticated-orcid":false,"given":"S.","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-8120","authenticated-orcid":false,"given":"S.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1970-7642","authenticated-orcid":false,"given":"D.","family":"Rauh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"76340_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40265-022-01820-1","volume":"83","author":"HM Khosroyani","year":"2023","unstructured":"Khosroyani, H. M., Klug, L. R. & Heinrich, M. C. TKI treatment sequencing in advanced gastrointestinal stromal tumors. Drugs 83, 55\u201373 (2023).","journal-title":"Drugs"},{"key":"76340_CR2","doi-asserted-by":"crossref","unstructured":"Incorvaia, L. et al. Type and gene location of KIT mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: a look into the exon. Cancers 13, (2021).","DOI":"10.3390\/cancers13050993"},{"key":"76340_CR3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/cncr.20862","volume":"103","author":"B Nilsson","year":"2005","unstructured":"Nilsson, B. et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103, 821\u2013829 (2005).","journal-title":"Cancer"},{"key":"76340_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00432-024-05965-2","volume":"150","author":"V Haller","year":"2024","unstructured":"Haller, V. et al. Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability. J. Cancer Res. Clin. Oncol. 150, 489 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"76340_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-015-0440-8","volume":"75","author":"S Bauer","year":"2015","unstructured":"Bauer, S. & Joensuu, H. Emerging agents for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors: current status and future directions. Drugs 75, 1323\u20131334 (2015).","journal-title":"Drugs"},{"key":"76340_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/path.2798","volume":"223","author":"CR Antonescu","year":"2011","unstructured":"Antonescu, C. R. The GIST paradigm: lessons for other kinase-driven cancers. J. Pathol. 223, 251\u2013261 (2011).","journal-title":"J. Pathol."},{"key":"76340_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali, P. G. et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 33, 20\u201333 (2022).","journal-title":"Ann. Oncol."},{"key":"76340_CR8","first-page":"1","volume":"42","author":"IM Schaefer","year":"2022","unstructured":"Schaefer, I. M., DeMatteo, R. P. & Serrano, C. The GIST of advances in treatment of advanced gastrointestinal stromal tumor. Am. Soc. Clin. Oncol. Educ. Book 42, 1\u201315 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"76340_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472\u2013480 (2002).","journal-title":"N. Engl. J. Med."},{"key":"76340_CR10","doi-asserted-by":"crossref","unstructured":"M\u00fchlenberg, T. et al. KIT ATP-binding pocket\/activation loop mutations in GI stromal tumor: emerging mechanisms of kinase inhibitor escape. J. Clin. Oncol. JCO2301197, (2024).","DOI":"10.1200\/JCO.23.01197"},{"key":"76340_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","volume":"120","author":"C Serrano","year":"2019","unstructured":"Serrano, C. et al. Complementary activity of tyrosine kinase inhibitors against secondary KIT mutations in imatinib-resistant gastrointestinal stromal tumours. Br. J. Cancer 120, 612\u2013620 (2019).","journal-title":"Br. J. Cancer"},{"key":"76340_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.  Lancet 368, 1329\u20131338 (2006).","journal-title":"Lancet"},{"key":"76340_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri, G. D. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.  Lancet 381, 295\u2013302 (2013).","journal-title":"Lancet"},{"key":"76340_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"J-Y Blay","year":"2020","unstructured":"Blay, J.-Y. et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.  Lancet Oncol. 21, 923\u2013934 (2020).","journal-title":"Lancet Oncol."},{"key":"76340_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44376-8","volume":"15","author":"A Teuber","year":"2024","unstructured":"Teuber, A. et al. Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA. Nat. Commun. 15, 63 (2024).","journal-title":"Nat. Commun."},{"key":"76340_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-20-0487","volume":"11","author":"S Grunewald","year":"2021","unstructured":"Grunewald, S. et al. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov. 11, 108\u2013125 (2021).","journal-title":"Cancer Discov."},{"key":"76340_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"MC Heinrich","year":"2020","unstructured":"Heinrich, M. C. et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 21, 935\u2013946 (2020).","journal-title":"Lancet Oncol."},{"key":"76340_CR18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1182\/blood.2021014612","volume":"140","author":"J Gotlib","year":"2022","unstructured":"Gotlib, J., Reiter, A. & DeAngelo, D. J. Avapritinib for advanced systemic mastocytosis. Blood 140, 1667\u20131673 (2022).","journal-title":"Blood"},{"key":"76340_CR19","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","volume":"26","author":"C Serrano","year":"2020","unstructured":"Serrano, C. & George, S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin. Cancer Res. 26, 5078\u20135085 (2020).","journal-title":"Clin. Cancer Res."},{"key":"76340_CR20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1177\/10668969231152588","volume":"31","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. A rare PDGFRA exon 15 germline mutation identified in a patient with phenotypic manifestations concerning for GIST-plus syndrome: a case report and review of literature. Int. J. Surg. Pathol. 31, 1139\u20131145 (2023).","journal-title":"Int. J. Surg. Pathol."},{"key":"76340_CR21","doi-asserted-by":"publisher","first-page":"14702","DOI":"10.1021\/acs.jmedchem.4c00361","volume":"67","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y., Kang, J. & Lu, X. Targeting solvent-front mutations for kinase drug discovery: from structural basis to design strategies. J. Med. Chem. 67, 14702\u201314722 (2024).","journal-title":"J. Med. Chem."},{"key":"76340_CR22","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1021\/acs.jmedchem.4c02472","volume":"68","author":"T Schulz","year":"2025","unstructured":"Schulz, T. et al. Design, synthesis, and SAR of covalent KIT and PDGFRA inhibitors horizontal line exploring their potential in targeting GIST. J. Med. Chem. 68, 3238\u20133259 (2025).","journal-title":"J. Med. Chem."},{"key":"76340_CR23","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"TW Johnson","year":"2014","unstructured":"Johnson, T. W. et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J. Med. Chem. 57, 4720\u20134744 (2014).","journal-title":"J. Med. Chem."},{"key":"76340_CR24","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1021\/jm1012374","volume":"54","author":"E Marsault","year":"2011","unstructured":"Marsault, E. & Peterson, M. L. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem. 54, 1961\u20132004 (2011).","journal-title":"J. Med. Chem."},{"key":"76340_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1021\/jm400887j","volume":"57","author":"F Giordanetto","year":"2014","unstructured":"Giordanetto, F. & Kihlberg, J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57, 278\u2013295 (2014).","journal-title":"J. Med. Chem."},{"key":"76340_CR26","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1021\/jacs.2c05377","volume":"144","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Morstein, J., Ecker, A. K., Guiley, K. Z. & Shokat, K. M. Chemoselective covalent modification of K-Ras(G12R) with a small molecule electrophile. J. Am. Chem. Soc. 144, 15916\u201315921 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"76340_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202422372","volume":"64","author":"P Chen","year":"2025","unstructured":"Chen, P. et al. Cell-active, arginine-targeting irreversible covalent inhibitors for non-kinases and kinases. Angew. Chem. Int. Ed. Engl. 64, e202422372 (2025).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"76340_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41589-023-01459-3","volume":"20","author":"M Reinecke","year":"2024","unstructured":"Reinecke, M. et al. Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors. Nat. Chem. Biol. 20, 577\u2013585 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"76340_CR29","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/nprot.2016.105","volume":"11","author":"MA Bray","year":"2016","unstructured":"Bray, M. A. et al. Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat. Protoc. 11, 1757\u20131774 (2016).","journal-title":"Nat. Protoc."},{"key":"76340_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. Xds. Acta Crystallogr. D. Biol. Crystallogr 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr"},{"key":"76340_CR31","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr 40, 658\u2013674 (2007).","journal-title":"J. Appl Crystallogr"},{"key":"76340_CR32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"76340_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"76340_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1021\/ci049885e","volume":"45","author":"G Wolber","year":"2005","unstructured":"Wolber, G. & Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model 45, 160\u2013169 (2005).","journal-title":"J. Chem. Inf. Model"},{"key":"76340_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/protein\/8.2.127","volume":"8","author":"AC Wallace","year":"1995","unstructured":"Wallace, A. C., Laskowski, R. A. & Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127\u2013134 (1995).","journal-title":"Protein Eng."},{"key":"76340_CR36","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1158\/0008-5472.CAN-08-4004","volume":"69","author":"T M\u00fchlenberg","year":"2009","unstructured":"M\u00fchlenberg, T. et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 69, 6941\u20136950 (2009).","journal-title":"Cancer Res."},{"key":"76340_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/acschembio.8b01020","volume":"14","author":"M Reinecke","year":"2019","unstructured":"Reinecke, M. et al. Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors. ACS Chem. Biol. 14, 655\u2013664 (2019).","journal-title":"ACS Chem. Biol."},{"key":"76340_CR38","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1021\/pr5012608","volume":"14","author":"G Medard","year":"2015","unstructured":"Medard, G. et al. Optimized chemical proteomics assay for kinase inhibitor profiling. J. Proteome Res. 14, 1574\u20131586 (2015).","journal-title":"J. Proteome Res"},{"key":"76340_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43696-z","volume":"14","author":"FP Bayer","year":"2023","unstructured":"Bayer, F. P., Gander, M., Kuster, B. & The, M. CurveCurator: a recalibrated F-statistic to assess, classify, and explore significance of dose-response curves. Nat. Commun. 14, 7902 (2023).","journal-title":"Nat. Commun."},{"key":"76340_CR40","doi-asserted-by":"publisher","first-page":"e80999","DOI":"10.1371\/journal.pone.0080999","volume":"8","author":"SM Gustafsdottir","year":"2013","unstructured":"Gustafsdottir, S. M. et al. Multiplex cytological profiling assay to measure diverse cellular states. PLoS One 8, e80999 (2013).","journal-title":"PLoS One"},{"key":"76340_CR41","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.chembiol.2021.12.009","volume":"29","author":"M Akbarzadeh","year":"2022","unstructured":"Akbarzadeh, M. et al. Morphological profiling by means of the Cell Painting assay enables identification of tubulin-targeting compounds. Cell Chem. Biol. 29, 1053\u20131064 e1053 (2022).","journal-title":"Cell Chem. Biol."},{"key":"76340_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.chembiol.2023.06.003","volume":"30","author":"A Pahl","year":"2023","unstructured":"Pahl, A. et al. Morphological subprofile analysis for bioactivity annotation of small molecules. Cell Chem. Biol. 30, 839\u2013853 e837 (2023).","journal-title":"Cell Chem. Biol."},{"key":"76340_CR43","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"76340_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"76340_CR45","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/s41596-023-00840-9","volume":"18","author":"BA Cimini","year":"2023","unstructured":"Cimini, B. A. et al. Optimizing the cell painting assay for image-based profiling. Nat. Protoc. 18, 1981\u20132013 (2023).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76340-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76340-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76340-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:11:34Z","timestamp":1786032694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76340-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76340"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76340-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. reports grants and personal fees from Blueprint Medicines, Incyte, and Novartis, PharmaMar, Eli Lilly & Co, Adcendo, Bayer, Blueprint Medicines, Boehringer Ingelheim, Cogent, Daiichi Sankyo, Deciphera, GSK, Exelixis, Novartis, Roche, PharmaMar. D.R. reports lecture and consulting fees from Pfizer, Sanofi, BI, and FLindr; is a shareholder of Centessa Pharmaceuticals plc., outside the submitted work. T.S., A.T., T.M., S.S., S.B, D.R. are co-inventors of a novel treatment against GIST (patent held by the respective institutions). The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7932"}}